Serial 90524944
Live / Registered — Registered (as of 26 Aug 2025)
What this means for you
Registered since 26 Aug 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90524944
- Registration number
- 7922036
- Mark type
- Design / logo
- Filed
- 11 Feb 2021
- Published for opposition
- 03 May 2022
- Registered
- 26 Aug 2025
- Attorney of record
- Connie L. Ellerbach
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; vaccine preparations; medical preparations for the treatment of infectious diseases, respiratory diseases, mucosal diseases, tumors, and cancer; pharmaceutical preparations and substances for the treatment of diseases and disorders, namely, infectious diseases, respiratory diseases, mucosal diseases, and cancer; chemical preparations for the treatment of diseases affecting mucosal tissues, the immune system, and respiratory tissues; chemical preparations for pharmaceutical purposes, namely, for, infectious diseases, respiratory diseases, mucosal diseases, tumors, and cancer; chemical preparations for medical purposes, namely, for autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, tumors, and cancer
- Class 010 — Medical apparatus: Medical devices to treat autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, multiple sclerosis, type 1 diabetes, tumors, and cancer; medical devices for administering vaccines pneumatically and parts thereof; vaccine apparatus comprised of devices for administering vaccines pneumatically; vaccine apparatus, namely, automatic vaccination apparatus
- Class 042 — Scientific and technological services: Research and development of vaccines; research and development of medicines, namely pharmaceutical research and development; research and development in the field of vaccination apparatus; medical research; scientific research; clinical research in the field of autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, multiple sclerosis, type 1 diabetes, immunotherapy, immune-oncology, chemotherapy, and anti-tumor agents
Owner
- Orlance, Inc., Seattle, WA, US
- Orlance, Inc., Seattle, WA, US
- Orlance, Inc., Seattle, WA, US
Prosecution history
- 26 Aug 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 26 Aug 2025 — REGISTERED-PRINCIPAL REGISTER
- 07 Aug 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 07 Aug 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 03 Jul 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 29 Jun 2025 — USE AMENDMENT FILED
- 29 Jun 2025 — TEAS STATEMENT OF USE RECEIVED
- 02 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Apr 2025 — SOU EXTENSION 5 GRANTED
- 13 Dec 2024 — SOU EXTENSION 5 FILED
- 28 Mar 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 13 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 20 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Jun 2024 — SOU EXTENSION 4 GRANTED
- 20 Jun 2024 — SOU EXTENSION 4 FILED